For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 3.0% in February Due to Flu Epidemic: Crecon Report
April 9, 2014
- Bayer Yakuhin Sales Up 16.5% Driven by New Product Growth
April 9, 2014
- Oncolys, BMS End Collaboration for Anti-HIV Drug Development
April 9, 2014
- Santen Licenses Tafluprost Marketing Rights in US to Oak Pharmaceuticals
April 9, 2014
- Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
- Daiichi Sankyo’s Governance over Ranbaxy Shaky to the End
April 8, 2014
- Novartis Gives Update on SIGN Probe, Personnel Change to JPMA
April 8, 2014
- Why Did Sanofi Decide to Begin Independent Marketing? Future Relationship with Nichi-Iko Remains in Doubt
April 8, 2014
- Japan Generic Market Put at 780 Billion Yen in 2016, Biosimilars 26.4 Billion Yen: Fuji Keizai
April 8, 2014
- India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard
April 7, 2014
- GSK’s Japan Unit Mulls Recalling Paxil after FDA Warning
April 7, 2014
- Astellas Seeks European Approval of XTANDI for Chemotherapy-Naïve Prostate Cancer Patients
April 7, 2014
- Latuda Approved for Bipolar Depression in Canada: DSP
April 7, 2014
- Gilead’s Novel Hepatitis C Drug Beats Primary Endpoint in PIII, Filing Slated for Mid-Year
April 7, 2014
- Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
- Sanofi Japan Sales Down 3.9% as Generics Take Toll
April 4, 2014
- Daiichi Sankyo Initiates Multinational ENSURE-AF Study of Edoxaban in the US, Europe
April 4, 2014
- Sawai Stands Out with Operating Profit Rate of 25% in 3rd Quarter, Moving into Top Level of the Industry
April 4, 2014
- Sales Rep Wrote Out Side Effect Grades for Doctors in SIGN Trial: Panel
April 3, 2014
- Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…